Jason Aryeh
CIK 1376960 · last filed 2026-06-05
Jason Aryeh is a corporate insider who has filed 170 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for LFCR, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$33.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $34.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$34.75M
11
170
-$33.00M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LFCR | Director | 69,967 | $5.64 | $394.6K | $0 | 3 | 2026-06-05 |
| OBIO | Director | 118,118 | $4.10 | $484.3K | $39.9K | 12 | 2026-05-20 |
| LGND | Director | 76,348 | $255.54 | $19.51M | -$30.56M | 66 | 2025-12-08 |
| Anebulo Pharmaceuticals, Inc. (ANEB) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-04-07 |
| MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | 10%+ Owner | 3,802 | $15.13 | $57.5K | $21.5K | 2 | 2019-07-18 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Director | 15,000 | — | — | $1.17M | 4 | 2017-05-24 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | 369,924 | — | — | $3.2K | 2 | 2017-05-17 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | — | — | — | $0 | 1 | 2017-01-10 |
| QLTI | Director | 535,478 | $26.82 | $14.36M | $1.05M | 18 | 2016-06-21 |
| Myrexis, Inc. (MYRX) Delisted | Director | 9,900 | — | — | $1.15M | 19 | 2012-06-20 |
| Vaxart, Inc. (NABI) Delisted | Director | 131,783 | — | — | -$5.87M | 39 | 2011-05-27 |
Recent Filings
170 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | LFCR | Grant (A) | +25,907 | $0 | EDGAR |
| 2026-05-20 | OBIO | Buy (P) | +665 | $2.5K | EDGAR |
| 2026-05-19 | OBIO | Buy (P) | +8,971 | $35.0K | EDGAR |
| 2025-12-08 | LGND | Exer (M) | +2,034 | $141.4K | EDGAR |
| 2025-09-24 | LGND | Sell (S) | −10,000 | -$1.71M | EDGAR |
| 2025-09-19 | OBIO | Buy (P) | +1,000 | $2.5K | EDGAR |
| 2025-08-08 | OBIO | Grant (A) | +15,000 | $0 | EDGAR |
| 2025-07-17 | LFCR | Grant (A) | +19,506 | $0 | EDGAR |
| 2025-06-27 | OBIO | Grant (A) | +12,422 | $0 | EDGAR |
| 2025-06-10 | LGND | Grant (A) | +1,209 | $0 | EDGAR |